Santa Rosa biotech company TriVascular Inc. has raised $7.2 million in fresh venture capital as it runs U.S. clinical trials on a new medical device. The company, which has raised more than $100 million in past rounds of venture funding, disclosed the latest deal in a filing with federal securities regulators earlier this month. TriVascular executives did not return telephone calls seeking comment Wednesday. Last year, TriVascular launched a third phase of U.S. clinical trials aimed at getting approval from the Food and Drug Administration to expand sales of its Ovation Abdominal Stent Graft, a system for repairing abdominal aortic aneurysms.
